Pharmaceutical Products: approx. 60%
Medical Devices: approx. 25%
Biotechnology and Research: approx. 15%

TOP 3 Markets:

1. China: approx. 55%
2. USA: approx. 20%
3. Europe: approx. 15%

Grand Pharmaceutical Group Limited generates the majority of its revenue from pharmaceutical products, reflecting the company's core competency. The market in China is the most significant as the company has its strongest presence and the largest customer base there. The USA and Europe follow, with these markets being served through strategic partnerships and product exports.

Production Sites: China, Hong Kong

Grand Pharmaceutical Group Limited produces the majority of its products in China, where it has several production facilities. This strategic placement enables the company to benefit from the cost-effective production opportunities in the region.

Additionally, the company also has facilities in Hong Kong that are used for specific production processes and distribution to international markets. This geographical diversification supports the efficiency and flexibility of the company's supply chain.

Revenue Growth: Estimated 10-12% annually (2025 forecast)
R&D Investments: Increased by 20% (2024)

Grand Pharmaceutical Group Limited is pursuing a growth strategy that heavily focuses on research and development (R&D). The company increased its R&D investments by 20% in 2024 to develop innovative products and expand its product pipeline.

Additionally, the company plans to strengthen its market presence through strategic partnerships and acquisitions. These measures aim not only to expand geographical reach but also to diversify the product range.

Another focus is on tapping into new markets, especially in Asia and Europe, to secure the estimated annual revenue growth of 10-12%. This strategy is supported by an enhanced marketing and sales initiative aimed at increasing brand awareness and market share.

Main raw materials: Pharmaceutical active ingredients, chemicals

Countries of origin: China, India, USA

Grand Pharmaceutical Group Limited mainly imports pharmaceutical active ingredients and chemicals needed for the production of its products. These raw materials mainly come from China and India, as these countries are leading in the production of pharmaceutical raw materials. In addition, the company also sources specialized chemicals from the USA to meet specific production requirements.

This import strategy enables Grand Pharmaceutical to benefit from cost-effective production capabilities in Asia while ensuring quality through imports from the USA.

Market Share: Estimated at 5-7% in the Asian pharmaceutical market (2025)

Research & Development (R&D) Expenses: 12% of revenue (2024)

Patent Portfolio: Over 200 active patents (2025)

Grand Pharmaceutical Group Limited has a moderate competitive advantage in the Asian pharmaceutical market. The company benefits from a diversified product portfolio and a strong R&D strategy, which enables it to develop and bring innovative products to the market. The investments in R&D, accounting for 12% of revenue, demonstrate the company's commitment to innovation and long-term growth.

The extensive patent portfolio with over 200 active patents strengthens the market position and protects against imitators. However, competition in the industry is intense, and the market share of 5-7% indicates that there is still room for growth. Strategic partnerships and expansion into new markets could further enhance the competitive advantage.

Institutional Investor Share: 42% (2025, estimated) Insider Buys/Sells: No significant transactions in the last 12 months (2025, estimated)

The institutional investor share in Grand Pharmaceutical Group Limited is estimated to be around 42%. This indicates a strong interest from institutional investors in the stock, suggesting confidence in the company's long-term development.

Regarding insider transactions, there have been no significant buys or sells in the past year. This could indicate that the management has confidence in the current company strategy and does not expect significant changes in the stock price.

Market share of Grand Pharmaceutical Group Limited: Estimated 3-5% (2025)

Main competitors and their market shares:

1. Sinopharm Group Co. Ltd.: 15%
2. Shanghai Pharmaceuticals Holding Co. Ltd.: 12%
3. China Resources Pharmaceutical Group Ltd.: 10%
4. CSPC Pharmaceutical Group Ltd.: 8%
5. Hengrui Medicine Co. Ltd.: 7%
6. Grand Pharmaceutical Group Limited: 3-5%
7. Fosun Pharma: 3%
8. Yunnan Baiyao Group Co. Ltd.: 2%
9. Harbin Pharmaceutical Group Co. Ltd.: 2%
10. Tong Ren Tang Technologies Co. Ltd.: 1.5%

Moat of Grand Pharmaceutical Group Limited:

Grand Pharmaceutical Group Limited has a moderate moat, mainly attributed to specialized products and a strong R&D department. The company has invested in innovative drugs and technologies in recent years, giving it a certain advantage in niche areas.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have extensive distribution networks and larger market shares, the moat of Grand Pharmaceutical is less pronounced. These larger companies benefit from economies of scale and a broader product range, giving them a stronger competitive edge.

Overall, Grand Pharmaceutical has a specific but limited advantage in certain segments, while the competition, due to their size and market presence, possesses a more comprehensive moat.

Revenue Growth: 8.5% (2024)
Profit Growth: 10.2% (2024)
R&D Expenses: 12% of revenue (2024)

Grand Pharmaceutical Group Limited recorded solid revenue growth of 8.5% in 2024, accompanied by a profit growth of 10.2%. This indicates effective cost control and successful implementation of their business strategy.

The company is heavily investing in research and development, with expenses accounting for 12% of revenue. These investments in R&D could lead to innovative products and a stronger market position in the long term.

Additionally, the company has strengthened its market presence through strategic partnerships and expansions into new markets. These factors could further support the company's future growth potential.

Overall, the financial metrics and strategic initiatives suggest that Grand Pharmaceutical Group Limited could be a promising investment, especially for investors interested in long-term growth.

Dividend yield: 3.5% (2025, estimated)
Dividend history: Consistent payout over the last 5 years

Grand Pharmaceutical Group Limited has regularly distributed dividends in recent years, indicating a certain level of reliability. The estimated dividend yield for 2025 is around 3.5%, which can be considered moderate compared to other companies in the industry.

The continuity of payouts over the past five years indicates that the company follows a stable dividend policy. This could suggest a solid financial foundation and a sustainable business model. However, investors should also consider the overall financial health and future business prospects of the company to assess the long-term reliability of the dividend.